PEG-MGF: what the published research shows
A research-use-only review of PEG-MGF (pegylated mechano growth factor), covering its formal nomenclature, the IGF-1 axis it is studied against, and the published evidence base, including where findings are animal-only o
PEG-MGF is the pegylated form of mechano growth factor (MGF), also referred to in the literature as pegylated IGF-1 Ec. It belongs to the IGF-1 (insulin-like growth factor-1) family of peptides and is supplied as a lyophilised research-grade material. The evidence block used for this page does not provide a sequence, molecular formula, or molecular weight for PEG-MGF, so none is stated here. The published work relevant to this compound centres on the GH-IGF-1 axis and on IGF-1 receptor-mediated signalling [1].
PEG-MGF is not a therapeutic product and has no approved clinical indication. The material is sold for laboratory research only. The studies cited below describe the GH-IGF-1 axis and related peptide classes; they do not establish efficacy, safety, or a dosing regimen for PEG-MGF in any population.
Research Studies
PEG-MGF and the GH-IGF-1 axis in performance-enhancing peptide research
The most directly relevant source in the evidence block is a review of performance-enhancing peptides that modulate the GH-IGF-1 axis [1]. That review describes the landscape of agents marketed as "research compounds" and intended to act on this axis. It names GHRH analogues (sermorelin, tesamorelin, CJC-1295 with and without DAC), growth hormone secretagogues (GHRP-2, GHRP-6, hexarelin, ipamorelin), the GH fragment AOD9604 (hGH 176-191), and IGF-1 analogues [1]. PEG-MGF sits within the IGF-1 analogue grouping by nomenclature, and the review frames the whole class as unregulated peptides encountered in clinical practice and in online self-administration protocols [1]. The review does not report PEG-MGF-specific outcome data.
PEG-MGF and pegylation as a pharmacokinetic strategy
Pegylation is a modification used to alter the behaviour of a peptide in circulation. The evidence block contains one clinical study of a pegylated growth hormone, PEG-somatropin (pegylated recombinant human growth hormone, PEG-rhGH), in children with Turner syndrome [8]. That study was designed to explore the optimal dose of PEG-rhGH injection, to preliminarily evaluate safety and efficacy, and to provide evidence for a Phase 3 medication dosage [8]. It is a study of PEG-rhGH, not of PEG-MGF, and it is included here only because it is the pegylated GH-IGF-1-axis agent with a clinical protocol in the evidence block. No PEG-MGF pharmacokinetic data are provided by the evidence block.
PEG-MGF and the IGF-1 analogue class: what the evidence block does and does not contain
The evidence block does not contain a PEG-MGF-specific study, an animal model of PEG-MGF administration, or an in vitro PEG-MGF experiment. Claims about PEG-MGF's mechanism at the tissue level, its half-life, or its effects in any model are therefore not made on this page. What the evidence block does support is the classification of PEG-MGF within the IGF-1 analogue group of GH-IGF-1-axis peptides [1].
PEG-MGF and the wider GH-IGF-1-axis peptide literature: comparator agents
To place PEG-MGF in context, the table below lists the GH-IGF-1-axis agents named in the review [1] alongside the pegylated growth hormone studied in Turner syndrome [8]. The table compares agent class and the population or model named in the source. It does not compare efficacy.
| Agent | Class | Population or model named in source | Source |
|---|---|---|---|
| Sermorelin | GHRH analogue | Named in review of performance-enhancing peptides | [1] |
| Tesamorelin | GHRH analogue | Named in review of performance-enhancing peptides | [1] |
| CJC-1295 (with and without DAC) | GHRH analogue | Named in review of performance-enhancing peptides | [1] |
| GHRP-2, GHRP-6, hexarelin, ipamorelin | Growth hormone secretagogues | Named in review of performance-enhancing peptides | [1] |
| AOD9604 (hGH 176-191) | GH fragment | Named in review of performance-enhancing peptides | [1] |
| IGF-1 analogues | IGF-1 analogue | Named in review of performance-enhancing peptides | [1] |
| PEG-rhGH (PEG-somatropin) | Pegylated recombinant human growth hormone | Children with Turner syndrome | [8] |
PEG-MGF and the limits of the current evidence base
The evidence block does not include a PEG-MGF study in humans, in animals, or in vitro. Any statement that PEG-MGF produces a specific effect in a specific tissue would therefore be unsupported by the sources available here. The review cited above describes the class and the regulatory context of these peptides but does not report PEG-MGF outcomes [1].
PEG-MGF and regulatory context for research peptides
The review characterises peptides marketed as "research compounds" as unregulated and notes that they are encountered both in clinical practice and in online self-administration protocols [1]. That framing is the regulatory context in which PEG-MGF is supplied. It is not a statement about PEG-MGF's safety or efficacy.
PEG-MGF and adjacent clinical research in the evidence block
The remaining sources in the evidence block concern conditions and compounds unrelated to PEG-MGF: trontinemab in early symptomatic Alzheimer's disease [2], a pre-screening study for Alzheimer's disease trial eligibility [3], semaglutide in early Alzheimer's disease (EVOKE [4] and EVOKE Plus [5]), lipoprotein(a) epidemiology in cardiovascular disease [6], and ticagrelor plus ASA in acute stroke or transient ischaemic attack [7]. None of these studies administered PEG-MGF or any IGF-1 analogue, and none reports data relevant to PEG-MGF. They are listed in Sources for completeness of the evidence block and are not used to support any claim about PEG-MGF on this page.
PEG-MGF and the pegylated GH-IGF-1-axis comparator in a paediatric population
The Turner syndrome study of PEG-rhGH enrolled children with Turner syndrome and was designed to explore optimal dose, to preliminarily evaluate safety and efficacy, and to provide evidence for a Phase 3 medication dosage [8]. That is a paediatric clinical population and a different molecule from PEG-MGF. It is the only source in the evidence block that describes a pegylated GH-IGF-1-axis agent in a defined clinical population, and it is presented here as a comparator for the pegylation strategy, not as evidence about PEG-MGF.
If you are reading this for personal health reasons
PEG-MGF is sold by this catalogue for laboratory research only, and we do not provide dosing or medical guidance for it. Nothing on this page is medical advice, and no statement here should be used to justify self-administration. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. https://europepmc.org/article/PMC/PMC13322892
- [2] A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease. https://clinicaltrials.gov/study/NCT07170150
- [3] Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies. https://clinicaltrials.gov/study/NCT07177352
- [4] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE). https://clinicaltrials.gov/study/NCT04777396
- [5] A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus). https://clinicaltrials.gov/study/NCT04777409
- [6] Lipoprotein(a) in Patients With Cardiovascular Disease (CVD). https://clinicaltrials.gov/study/NCT03887520
- [7] THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death. https://clinicaltrials.gov/study/NCT03354429
- [8] A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome. https://clinicaltrials.gov/study/NCT03189160